INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$0.35
+0.01 (+3.01%)
Open$0.35
Previous Close$0.34
Day High$0.36
Day Low$0.34
52W High$47.47
52W Low$20.23
Volume—
Avg Volume765.8K
Market Cap20.96M
P/E Ratio23.23
EPS$1.45
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+10,501.7% upside
Current
$0.35
$0.35
Target
$37.00
$37.00
$31.85
$37.00 avg
$43.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |
| Rev Growth | +8.4% | -9.6% | +19.4% |
| Debt/Equity | 0.32 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |